Notes to the consolidated financial statements 16 Property, plant and equipment continued Impairment losses It is the Groups policy to test assets for impairment whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable.
a Impact of changes to the EU sugar regime The Group continues to monitor the impact of the announced changes to the EU sugar regime, which were implemented in July 2006 and significantly reduce both EU refined sugar prices, raw sugar prices, and EU subsidised exports of sugar.
The UK and Portuguese Sugars businesses are impacted by the proposed changes to the EU sugar regime.
Managements impairment review of these businesses was based on internal forecasts of future cash flows for the next five years, a pre-tax discount rate of 11% 2007 12% and a zero growth rate assumed in perpetuity.
This did not result in an impairment in either the year ended 31 March 2007 or 31 March 2008.
Food & Industrial Ingredients, Europe is a major supplier of sweeteners which operates in competition to sugar throughout Europe.
Following the disposal of five European starch plants in October 2007, the Group carried out an impairment review in respect of the remaining cash generating units.
Recoverable amount was based on value in use, calculated based on estimated future cash flows using managements internal forecasts of future margins for the next five years.
The pre-tax discount rate used was 10% 2007 12% and a zero growth rate assumed in perpetuity.
Taking all factors into account management concluded that no further impairment or reversal of previous impairments were required.
b Other impairment reviews The Group has carried out a review of its global citric acid business following on from the closure of its citric acid facility in Selby, UK in October 2007 and as a result of intense competition from Chinese exports and oversupply in the world market.
The recoverable amount was based on value in use, calculated based on managements internal forecasts of future cash flows for the next ten years, a pre-tax discount rate of 12%.
As a result, an impairment charge of 12 million has been recognised relating to property, plant and equipment.
This charge is included in exceptional items relating to continuing business.
In addition, the Groups monosodium glutamate business in China, Orsan GGP, suffered from an over-supplied market with increased industry capacity coming on stream and a change in tax incentives discouraging exports.
Given the uncertainty that market conditions will recover in the short term, the Group has taken an impairment charge of 17 million through continuing exceptional items to write the business down to its recoverable amount.
10 million of this impairment relates to minority interest.
The recoverable amount was based on managements internal forecasts of future cash flows for the next five years, a pre-tax discount rate of 14% and a zero growth rate assumed in perpetuity.
9 million of this charge relates to property, plant and equipment.
Leased assets Included in property, plant and equipment is plant and machinery held under finance leases with a net book value of 22 million 2007 22 million.
During the year ended 31 March 2008, 2 million of additions were recognised on the inception of finance leases 2007 14 million.
Capitalised borrowing costs The aggregate amount of borrowing costs included in the cost of property, plant and equipment is 21 million 2007 46 million, of which 8 million 2007 7 million was capitalised during the year.
17 Investments in associates and joint ventures Total Associates m At 1 April 2006 4 Additions 3 At 31 March 2007 and at 31 March 2008 7 The Groups associates, which are equity accounted, are listed in Note 43.
The Group owns an overall holding of 14% in Microbia Precision Engineering Inc.
The Group considers the investment to be an associate due to the Groups ability to exercise significant influence over the company.
Tate & Lyle Annual Report 2008 119 STATUTORY INFORMATION HOW WE RUN THE BUSINESS HOW WE PERFORMED WHAT WE DO OVERVIEW OF THE YEAR Notes to the consolidated financial statements 17 Investments in associates and joint ventures continued The amounts equity accounted in the Group income statement and balance sheet are summarised below: Income statement Year to 31 March 2008 2007 m m Sales 2 4 Expenses 2 4 Profit before tax Income tax expense Profit for the year Balance sheet 31 March 2008 2007 m m Assets 19 14 Liabilities 12 7 Net assets 7 7 Joint ventures The Groups joint ventures are proportionately consolidated and the continuing businesses are listed in Note 43.
The amounts proportionately consolidated in the Group income statement and balance sheet are summarised below: Income statement Year to 31 March 2008 Year to 31 March 2007 Continuing Discontinued Continuing Discontinued operations operations operations operations m m m m Sales 247 107 201 188 Expenses 227 91 175 138 Profit before tax 20 16 26 50 Income tax expense 6 10 8 9 Profit for the year 14 6 18 41 Balance sheet 31 March 2008 2007 m m Assets Non-current assets 160 221 Cash and cash equivalents 51 45 Other current assets 184 183 395 449 Liabilities Non-current borrowings 4 4 Other non-current liabilities 28 45 Current borrowings 41 25 Other current liabilities 44 61 117 135 Net assets 278 314 The Groups proportionate interest in joint ventures commitments and contingent liabilities was 14 million 2007 11 million.
